Rhythm Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Rhythm Pharmaceuticals's estimated annual revenue is currently $5.9M per year.(i)
  • Rhythm Pharmaceuticals received $41.0M in venture funding in February 2017.
  • Rhythm Pharmaceuticals's estimated revenue per employee is $30,051
  • Rhythm Pharmaceuticals's total funding is $637.7M.

Employee Data

  • Rhythm Pharmaceuticals has 196 Employees.(i)
  • Rhythm Pharmaceuticals grew their employee count by 23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. Rhythm's lead product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist. Rhythm supports The Genetic Obesity Project (GeneticObesity.com) and the GO-ID Genotyping Study (GeneticObesityID.com).

keywords:Biotechnology,Enterprise Software,Healthcare,Human Resources Hr,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Rhythm Pharmaceuticals News

2022-04-17 - Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ...

Needham & Company LLC dropped their price target on Rhythm Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a...

2022-04-13 - Rhythm Pharmaceuticals Announces New Employment ...

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company...

2022-04-06 - Rhythm Pharmaceuticals Optimizes Design of EMANATE and ...

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity.

2021-09-22 - Rhythm Pharmaceuticals : Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome -- -- Efficacy results from complete topline analyses of Rhythm’s Phase 2 Basket Study show wei ...

2020-01-07 - Rhythm CEO Kei­th Gottes­di­ener hits the ex­it; Take­da sets up an AI dis­cov­ery pro­gram at MIT

→ Rhythm Phar­ma­ceu­ti­cals $RYTM CEO Kei­th Gottes­di­ener is plan­ning to stay at the helm un­til the biotech com­pletes its new drug ap­pli­ca­tion, and then head out. He says it’s the right time to hand over the reins and the com­pa­ny plans to or­ga­nize a search for his re­place­ment. His ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Rhythm Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2010-09-09$40.0MAMPM Capital, New Enterprise AssociatesArticle
2012-06-14$25.0MBMPM Capital, New Enterprise AssociatesArticle
2012-11-28$8.0MUndisclosedPfizer Venture InvestmentsArticle